Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 19 - Drugs for skeletal disorders
Patents for A61P 19 - Drugs for skeletal disorders (81,981)
03/2003
03/26/2003EP1294700A2 Benzhydryl derivatives
03/26/2003EP1294699A2 Modulators of tnf- alpha signalling
03/26/2003EP1294696A2 Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases
03/26/2003EP1294691A1 Serine protease inhibitors
03/26/2003EP1294690A2 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
03/26/2003EP1294688A2 Indolinone derivatives as protein kinase/phosphatase inhibitors
03/26/2003EP1294687A2 1,2,4-trisubstituted benzenes as inhibitors of 15-lipoxygenase
03/26/2003EP1294686A2 Indole derivatives and their use as 15-lipoxygenase inhibitors
03/26/2003EP1294681A2 Fmoc-l-leucine and derivatives thereof as ppar- gamma agonists
03/26/2003EP1294679A1 Beta-amino acid nitrile derivatives
03/26/2003EP1294409A2 Membrane-permeant peptide complexes for medical imaging
03/26/2003EP1294389A1 THERAPEUTICAL USE OF i SOPHORA FLAVESCENS /i OR i SOPHORA SUBPROSTRATA /i EXTRACTS
03/26/2003EP1294388A1 EXTRACTS FROM i SOPHORA /i SPECIES, METHOD FOR PRODUCING THE SAME AND THEIR USE
03/26/2003EP1294384A2 Use of lanthanum compounds for the treatment of bone diseases
03/26/2003EP1212315B1 Novel chalcones
03/26/2003EP1212311B1 Chalcone coumarins
03/26/2003EP1105384B1 Diarylbenzopyran derivatives as cyclooxygenase-2 inhibitors
03/26/2003EP1005378B1 Semi-interpenetrating polymer networks
03/26/2003EP0998454B1 Metalloproteinase inhibitors
03/26/2003EP0977735B1 Vitronectin receptor antagonists
03/26/2003EP0930310B1 Isocoumarin derivatives and use thereof in drugs
03/26/2003EP0863757B1 2-substituted aryl pyrroles, compositions containing such compounds and methods of use
03/26/2003CN1406230A 2,4-di (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents
03/26/2003CN1406229A Pyrimidine compounds
03/26/2003CN1406225A Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists
03/26/2003CN1406127A Thiazolium compounds and treatments of disorders associated with protein aging
03/26/2003CN1405144A 由海龙科动物提取的海龙素及其制法和用途 Dragon species extracted by Dragon hormone preparation and use
03/26/2003CN1404871A Chinese medicinal plaster for treatment of bone-fracture
03/26/2003CN1404863A Medicine for treating ischemic necrosis of head of femur and preparation method thereof
03/26/2003CN1404836A Use of Aiben sodium phosphonate as effective component of medicine for preventing and treating osteoporosis
03/26/2003CN1404826A Method for preparing naproxen sodium release tablet
03/26/2003CN1103775C Vitronectin receptor antagonists, their preparation and use
03/26/2003CN1103756C Estrogenic agents
03/26/2003CN1103755C Novel structural analogues of vitamin D
03/25/2003US6538121 Interleukin-1 β converting enzyme like apoptosis protease-3 and 4
03/25/2003US6538009 Pyrazole derivatives as anti-inflammatory/analgesic agents
03/25/2003US6537984 Contacting a targeted solid tumor cell population with a combination of a vinca alkaloid selected from vinblastine, vincristine, vinorelbine, and a triptolide in combination dosage to reduce the targeted tumor cell population
03/25/2003US6537980 Vitamin D analogues and their pharmaceutical use
03/25/2003US6537965 Novel parathyroid hormone (PTH) peptide derivatives. In particular, the invention relates to PTH PTH-2 receptor agonist or antagonist properties to the derivatives.
03/25/2003US6537589 Calcium phosphate artificial bone as osteoconductive and biodegradable bone substitute material
03/25/2003US6537540 Administering recombinant adeno-associated virus vector; polynucleotide encoding fusion polypeptide with extracellular domain of the TNF receptor and a constant domain of an IgG1 molecule
03/25/2003CA2149052C Dry mix formulation for bisphosphonic acids
03/20/2003WO2003023008A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
03/20/2003WO2003022877A1 Crystal structure of baff, and use thereof in drug design
03/20/2003WO2003022852A2 Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
03/20/2003WO2003022842A1 Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors
03/20/2003WO2003022814A1 Indole derivatives
03/20/2003WO2003022801A1 Reverse hydroxamic acid derivatives
03/20/2003WO2003022787A1 Method for preparing unsaturated fatty hydroxy-acids and esters thereof, their use in pharmaceutical and/or cosmetic compositions
03/20/2003WO2003022360A2 Thermotherapy via targeted delivery of nanoscale magnetic particles
03/20/2003WO2003022300A1 Preventives/remedies for bone/joint diseases
03/20/2003WO2003022296A1 Method and composition for treating immune complex associated disorders
03/20/2003WO2003022292A1 Oral pharmaceutical formulation containing active carbon and use of the same
03/20/2003WO2003022291A1 Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
03/20/2003WO2003022273A1 Methods of treating cytokine mediated diseases
03/20/2003WO2003022271A1 Lymphocytic activation inhibitor and remedial agent for autoimmune disease
03/20/2003WO2003022266A1 Hypoestoxides, derivatives and agonists thereof for use as inhibitors of angiongenesis
03/20/2003WO2003022259A1 Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
03/20/2003WO2003022216A2 Biaryl substituted purine derivatives as potent antiproliferative agents
03/20/2003WO2003000011A3 Novel pyridopyrimidines and uses thereof
03/20/2003WO2002096366A3 Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
03/20/2003WO2002094342A3 Compositions for protein delivery via the pulmonary route
03/20/2003WO2002091993A3 Estrogen receptor modulators
03/20/2003WO2002087424A3 Treatment and diagnosis of macrophage mediated disease
03/20/2003WO2002085285A3 Methods and reagents for regulating bone and cartilage formation
03/20/2003WO2002079404A3 Cytoskeleton-associated proteins
03/20/2003WO2002067865A3 N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof
03/20/2003WO2002060393A3 Proteoglycan compositions for treatment of inflammatory conditions
03/20/2003WO2002050255A3 Isolated human dehydrogenases, nucleic acid molecules encoding them, and uses thereof
03/20/2003WO2002047697A8 Fractions of snake blood, their preparation and use as therapeutic agents
03/20/2003WO2002020736A3 Proteases
03/20/2003WO2002020718A9 Osteoclast-associated receptor
03/20/2003WO2002018445A9 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
03/20/2003WO2001070253A8 Use of mia in immunotherapy
03/20/2003US20030055286 Il-8 receptor antagonists
03/20/2003US20030055275 Prevention of neutrophil recruitment
03/20/2003US20030055261 Compounds with growth hormone releasing properties
03/20/2003US20030055260 Il-8 receptor antagonists
03/20/2003US20030055250 Pteridine compounds for the treatment of psoriasis
03/20/2003US20030055248 Il-8 receptor antagonists
03/20/2003US20030055246 Serine protease inhibitors
03/20/2003US20030055111 For use in preparation of medicaments for the treatment of tumors and rheumatoid arthritis
03/20/2003US20030055101 Use of statins to inhibit formation of osteoclasts
03/20/2003US20030055098 Method of treatment
03/20/2003US20030055093 For therapy of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction
03/20/2003US20030055068 Pyrazole compounds useful as protein kinase inhibitors
03/20/2003US20030055064 Piperazine compounds and medicinal use thereof
03/20/2003US20030055056 For use as antitumor and immune suppressive agents, as inhibitors of proliferative cell growth and as prophylactic agents to inhibit and prevent cancer and non-malignant cell growth
03/20/2003US20030055054 CXCR3 antagonists
03/20/2003US20030055044 Administering pyrazole derivative for inhibiting GSK-3 or Aurora activity in a patient
03/20/2003US20030055030 Administering 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride for therapy of inflammatory disease or inflammation-associated disorder
03/20/2003US20030055024 Administering in divided doses an effective amount of a vascular damaging agent or a pharmaceutically acceptable salt thereof for production of a vascular damaging effect in a warm-blooded animal such as a human
03/20/2003US20030055006 Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/tie receptor function and their use
03/20/2003US20030055003 Administering copper chelator and activated protein C (APC) or protein C or agent that increases the synthesis of protein C in the animal, or both, an activator of protein C for therapy
03/20/2003US20030054439 Truncated soluble tumor necrosis factor type-I and type-II receptors
03/20/2003US20030054058 Vitex agnus castus extract
03/20/2003US20030054046 Hydrated dressing containing metal microbiocide
03/20/2003CA2460348A1 Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
03/20/2003CA2459890A1 Crystal structure of baff, and use thereof in drug design
03/20/2003CA2459882A1 Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors
1 ... 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 ... 820